ZGNX Zogenix Inc.

Zogenix to Participate in the 31st Annual Piper Jaffray Healthcare Conference

Zogenix to Participate in the 31st Annual Piper Jaffray Healthcare Conference

EMERYVILLE, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., will participate in a fireside chat on Thursday, December 5, 2019, at the 31st Annual Piper Jaffray Healthcare Conference, taking place December 3-5, 2019, in New York City.

Zogenix Fireside Chat Details
Date: Thursday, December 5, 2019
Location: Lotte New York Palace Hotel
Time: 10:00 AM Eastern Time
Webcast: The fireside chat will be webcast live and archived for 90 days on Zogenix's Investor Relations website at

About Zogenix

Zogenix is a global pharmaceutical company committed to developing and commercializing transformative therapies to improve the lives of patients and their families living with rare diseases. The Company has two late-stage development programs underway: FINTEPLA® (fenfluramine) for the treatment of seizures associated with Dravet and Lennox-Gastaut syndromes, two rare and often-catastrophic childhood-onset epilepsies. Additionally, Zogenix is in clinical development with MT1621, a novel, investigational substrate enhancement therapy for the treatment of a rare genetic disorder called TK2 deficiency. The U.S. Food & Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for FINTEPLA for the treatment of seizures associated with Dravet syndrome. The FDA granted Priority Review for the NDA for FINTEPLA. The marketing authorization application for FINTEPLA for Dravet syndrome is under review by the European Medicines Agency. Zogenix expects top-line data results from its Phase 3 study of FINTEPLA in Lennox-Gastaut syndrome in the first quarter of 2020. FINTEPLA is also in development in Japan for Dravet and Lennox-Gastaut syndromes.

CONTACTS:

Zogenix

Melinda Baker

Senior Director, Corporate Communications

+1 (510) 788-8732  | 

Investors

Andrew McDonald

Founding Partner, LifeSci Advisors LLC

+1 (646) 597-6987 |

EN
27/11/2019

Underlying

ZGNXZogenix Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zogenix Inc.

 PRESS RELEASE
Free
ZGNX ZOGENIX INC.

Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in L...

Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022 Two podium and one poster presentation share important new findings on FINTEPLA’s safety profile and its impact on non-seizure related benefits for LGS patientsLGS is a debilitating childhood-onset developmental and epileptic encephalopathy estimated to affect approximately 30,000-50,000 patients in the U.S.1 EMERYVILLE, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, a...

March 4, 2022 1 EN
 PRESS RELEASE
Free
ZGNX ZOGENIX INC.

Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-...

Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results Total revenue of $26.6 million in the fourth quarter and $81.7 million for the full yearFINTEPLA® net product sales of $23.5 million in the fourth quarter and $74.7 million for the full year Announced U.S. Food and Drug Administration acceptance with Priority Review of Supplemental New Drug Application for FINTEPLA in Lennox-Gastaut Syndrome (LGS)Submitted Type II Variation Application to the European Medicines Agency to expand the use of FINTEPLA for LGSSubmitted New Drug Application to Japan’...

February 28, 2022 1 EN
 PRESS RELEASE
Free
ZGNX ZOGENIX INC.

Zogenix Supports New No-Cost Genetic Testing Program with United Mitoc...

Zogenix Supports New No-Cost Genetic Testing Program with United Mitochondrial Disease Foundation to Improve Diagnosis of Mitochondrial Diseases Symptoms of mitochondrial diseases, such as Thymidine Kinase 2 deficiency (TK2d), can vary widely and mimic other rare and common diseases, making diagnosis challenging 1,2,3Genetic testing offers a quicker, confirmatory path to diagnosis, enabling more accurate care and participation in available clinical trials 1,2,3An estimated 1 in 5,000 individuals has a genetic mitochondrial disease 4 EMERYVILLE, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Z...

February 15, 2022 1 EN
 PRESS RELEASE
Free
ZGNX ZOGENIX INC.

Zogenix Submits New Drug Application for FINTEPLA® (Fenfluramine) in J...

Zogenix Submits New Drug Application for FINTEPLA® (Fenfluramine) in Japan for the Treatment of Epileptic Seizures Associated with Dravet Syndrome EMERYVILLE, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Zogenix, a global biopharmaceutical company specializing in rare disease therapies, announced that it has submitted a New Drug Application (J-NDA) to the Japanese Ministry of Health, Labour & Welfare (MHLW) for the marketing approval of FINTEPLA® (fenfluramine) for the treatment of epileptic seizures associated with Dravet syndrome in Japan. FINTEPLA received Orphan Drug Designation from Jap...

December 21, 2021 1 EN
 PRESS RELEASE
Free
ZGNX ZOGENIX INC.

Zogenix Submits Type II Variation Application to the European Medicine...

Zogenix Submits Type II Variation Application to the European Medicines Agency (EMA) to Expand the Use of FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome EMERYVILLE, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that it has submitted its Type II Variation Market Authorization Application to the European Medicines Agency (EMA) for FINTEPLA® for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a h...

December 20, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch